CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.

摘要: Objective  The aim of this study is to determine serum levels soluble forms CD26/dipeptidyl-peptidase IV (DPP-IV) and adenosine deaminase (ADA), thought be markers T-cell activation, changes in their response cyclosporine, etanercept, psoralen plus ultraviolet A (PUVA) treatments with respect disease activity. Methods  This designed as a prospective clinical control group three months follow-up. included 41 patients psoriasis healthy controls that were older than 18 years age. There three different treatment groups: PUVA (n = 15), cyclosporine etanercept (n = 11). To severity psoriasis, area index (PASI) scores calculated. Results  Only mean ADA between [mean ± standard deviation (SD) = 13.9 ± 3.3 U/ml] (mean ± SD = 12 ± 3.5 U/ml). Mean significantly higher before after (mean ± SD = 12.4 ± 3.4 U/ml). Contrarily, following therapy, CD26 increased from 777.7 ± 214.6 835.3 ± 203 ng/ml (P < 0.05) DPP-IV activity 12.1 ± 4 15.9 ± 4.2 nmol/min (P < 0.05). was no correlation CD 26/DPP-IV PASI values. Conclusions  results show might useful marker indicating activation. As significant observed CD26/DPP-IV treatment, we think play role pathogenesis, which should clarified by further studies.